Telix Pharmaceuticals Ltd (ASX: TLX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Telix Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$3.26 billion
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
323.40 million
Earnings per share
-0.149
Dividend per share
N/A
Year To Date Return
32.32%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Telix Pharmaceuticals Ltd (ASX: TLX)
Latest News
Share Market News
Here are the top 10 ASX 200 shares today
Share Market News
Here are the top 10 ASX 200 shares today
Growth Shares
Could buying these ASX shares at $9 now be like investing in Tesla in 2010?
Investing Strategies
Invest in these 2 ASX shares for a real shot at $1 million
Share Market News
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Cheap Shares
7 oversold ASX shares to buy in November 2023
Share Fallers
Telix Pharmaceuticals share price sinks 12% despite rocketing revenue
Share Fallers
Why AMP, Netwealth, Pilbara Minerals, and Telix shares are dropping today
Share Market News
5 things to watch on the ASX 200 on Thursday
Investing Strategies
ASX passive income of $200 a week? See how you can do it for $5 per day
Growth Shares
20% a year? 3 ASX growth shares that doubled in 4 years
Frequently Asked Questions
-
No, Telix does not pay dividends at this time.
-
Telix Pharmaceuticals Ltd listed on the ASX on 15 November 2017.
TLX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd (ASX: TLX) is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic ('theranostic') products using targeted radiation. This process treats cancerous or diseased cells, an alternative approach to many cancer therapies which also attack healthy tissue at the same time.
Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent Illuccix. It is working to get Illuccix approved for sale in the UK and Europe.
The company also has more than 20 clinical trials underway worldwide. Telix's research and development is focused on prostate, renal (kidney), glioblastoma (brain), and hematologic (bone marrow conditioning) cancers, as well as rare diseases. The company is headquartered in Australia with offices in Belgium, Japan, Switzerland, and the United States.
TLX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 30 Nov 2023 | $10.08 | $0.41 | 4.24% | 1,557,023 | $9.84 | $10.12 | $9.76 |
| 29 Nov 2023 | $9.67 | $0.05 | 0.52% | 476,116 | $9.72 | $9.72 | $9.46 |
| 28 Nov 2023 | $9.62 | $0.22 | 2.34% | 415,702 | $9.31 | $9.65 | $9.31 |
| 27 Nov 2023 | $9.40 | $0.03 | 0.32% | 1,589,339 | $9.41 | $9.45 | $9.33 |
| 24 Nov 2023 | $9.37 | $0.19 | 2.07% | 249,088 | $9.25 | $9.41 | $9.20 |
| 23 Nov 2023 | $9.18 | $0.04 | 0.44% | 524,349 | $9.14 | $9.41 | $9.12 |
| 22 Nov 2023 | $9.14 | $-0.22 | -2.35% | 528,072 | $9.38 | $9.39 | $9.09 |
| 21 Nov 2023 | $9.36 | $0.23 | 2.52% | 761,558 | $9.31 | $9.47 | $9.20 |
| 20 Nov 2023 | $9.13 | $-0.26 | -2.77% | 1,057,112 | $9.56 | $9.60 | $9.03 |
| 17 Nov 2023 | $9.39 | $0.38 | 4.22% | 852,023 | $9.20 | $9.55 | $9.15 |
| 16 Nov 2023 | $9.01 | $-0.22 | -2.38% | 721,313 | $9.26 | $9.26 | $8.94 |
| 15 Nov 2023 | $9.23 | $-0.05 | -0.54% | 469,444 | $9.40 | $9.51 | $9.21 |
| 14 Nov 2023 | $9.28 | $0.13 | 1.42% | 411,210 | $9.40 | $9.43 | $9.22 |
| 13 Nov 2023 | $9.15 | $-0.30 | -3.17% | 657,093 | $9.50 | $9.56 | $9.15 |
| 10 Nov 2023 | $9.45 | $-0.12 | -1.25% | 536,771 | $9.45 | $9.58 | $9.38 |
| 09 Nov 2023 | $9.57 | $0.02 | 0.21% | 618,259 | $9.65 | $9.79 | $9.49 |
| 08 Nov 2023 | $9.55 | $0.16 | 1.70% | 805,745 | $9.60 | $9.62 | $9.43 |
| 07 Nov 2023 | $9.39 | $0.15 | 1.62% | 436,563 | $9.25 | $9.41 | $9.20 |
| 06 Nov 2023 | $9.24 | $0.00 | 0.00% | 850,876 | $9.30 | $9.43 | $9.21 |
| 03 Nov 2023 | $9.24 | $0.14 | 1.54% | 857,962 | $9.24 | $9.45 | $9.18 |
| 02 Nov 2023 | $9.10 | $0.12 | 1.34% | 490,429 | $9.14 | $9.21 | $9.03 |
| 01 Nov 2023 | $8.98 | $0.14 | 1.58% | 857,911 | $8.99 | $9.12 | $8.93 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 30 May 2023 | Christian Behrenbruch | Issued | 120,268 | $356,738 |
Director remuneration. Black Scholes valuation, 2,59,940 rIGHTS
|
| 16 Mar 2023 | Tiffany Olson | Buy | 51,305 | $343,385 |
On-market trade. average price
|
| 12 Dec 2022 | Tiffany Olson | Buy | 10,930 | $73,255 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Harry Kevin McCann | Non-Executive ChairmanNon-Executive Director | Sep 2017 |
Mr McCann has board experience with some of Australia's recognised companies. Kevin is a former corporate lawyer and experienced Chairman and Director of listed private and government companies and government agencies. Previously, Kevin has been Chairman of Macquarie Group and Macquarie Bank Limited, Chairman of Origin Energy Limited, Healthscope Limited, the Sydney Harbour Federation Trust and a Director of Bluescope Steel. He is Chair of People, Culture and Disclosure Committee and member of Risk Committee.
|
| Ms Jann E Skinner | Non-Executive Director | Jun 2018 |
Ms Skinner has experience in audit and accounting and in the insurance industry. She was a partner of PricewaterhouseCoopers for 17 years before retiring in 2004. Jann is an independent Non-Executive Director of QBE Insurance Group Limited, where she also serves as Chair of the Audit Committee and Deputy Chair of the Risk and Capital Committee. She also serves as a Director of the Create Foundation Limited and HSBC Bank Australia Limited. He is the Chair of Risk Committee and member of People, Culture and Disclosure Committee (for financial related disclosures).
|
| Dr Christian Peter Behrenbruch | Chief Executive OfficerManaging Director | Jan 2017 |
Dr Behrenbruch has over twenty years of healthcare entrepreneurship and executive leadership experience. He has previously served in a CEO or Executive Director capacity at Mirada Solutions, CTI Molecular Imaging (now Siemens Healthcare), Fibron Technologies and ImaginAb, Inc. He is a former Director of Momentum Biosciences LLC, Siemens Molecular Imaging Ltd, Radius Health Ltd (Adaptix) and was the former Chairman of Cell Therapies Pty Ltd (a partnership with the Peter MacCallum Cancer Centre). He is a member of Disclosure Committee.
|
| Dr Andreas Kluge | Non-Executive Director | Jan 2017 |
Dr Kluge has over 20 years of clinical research and development experience, including as Founder, General Manager and Medical Director for ABX-CRO, a full service CRO for Phase I-III biological, radiopharmaceutical, and anticancer trials based in Dresden, Germany. He is also Founder and was founding CEO of ABX GmbH (www.abx.de), one of the manufacturers of radiopharmaceutical precursors globally. Andreas is further Founder, General Manager and Medical Director for Therapeia, an early-stage development company in the field of neurooncology, which was acquired by Telix. Andreas has experience in the practice of Nuclear Medicine and radiochemistry, molecular imaging and the clinical development of novel radionuclide-based products and devices.
|
| Dr Mark Alexander Nelson | Non-Executive Director | Sep 2017 |
Dr Nelson is Chairman and Co-Founder of the Caledonia Investments Group, and a Director of The Caledonia Foundation. Previously Mark was a Director of The Howard Florey Institute of Experimental Physiology and Medicine and served on the Commercialisation Committee of the Florey Institute. He is a member of Risk, People and Culture Committee.
|
| Ms Tiffany Olson | Non-Executive Director | Mar 2022 |
Ms Olson brings experience in commercialisation and corporate strategy in oncology, including in the radiopharmaceutical sector. Her most recent executive role was with Cardinal Health, the provider of radiopharmaceuticals in the United States, where she was President of Cardinal Health Nuclear and Precision Health Solutions overseeing Cardinal's radiopharmaceutical manufacturing and nuclear pharmacy network. During her eight-year tenure in this role she led a major business transformation which led to increased market share and profit growth. Prior to her role at Cardinal Health, Ms. Olson served as President of NaviMed and in executive roles at Eli Lilly and Roche, where she attained the position of President and CEO of Roche Diagnostics Corporation. She is a member of Risk Committee.
|
| Ms Genevieve Ryan | Company Secretary | Dec 2022 |
-
|
| Genevieve Ryan | Company Secretary |
-
|
|
| Richard Valeix | Group Chief Commercial Officer |
-
|
|
| Darren Smith | Group Chief Financial Officer |
-
|
|
| Colin Hayward | Group Chief Medical Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 40,150,674 | 12.68% |
| Citicorp Nominees Pty Limited | 31,011,771 | 9.79% |
| J P Morgan Nominees Australia Pty Limited | 27,441,529 | 8.66% |
| Elk River Holdings Pty Ltd As Trustee For The Behrenbruch Family Trust And C Behrenbruch | 22,675,000 | 7.16% |
| Gnosis Verwaltungsgesellschaftm B H | 22,675,000 | 7.16% |
| National Nominees Limited | 12,886,518 | 4.07% |
| Grand Decade Developments Limited | 10,947,181 | 3.46% |
| Uv Cap Gmbh and Co Kg | 7,525,000 | 2.38% |
| BNP Paribas Nominees Pty Ltd | 6,675,428 | 2.11% |
| The Oncidium Foundation | 6,239,360 | 1.97% |
| BNP Paribas Noms Pty Ltd | 5,443,420 | 1.72% |
| Scintec Diagnostics Gmbh | 4,312,151 | 1.36% |
| Hsbc Custody Nominees (Australia) Limited A/C 2 | 3,673,399 | 1.16% |
| BNP Paribas Nominees Pty Ltd Acf Clearstream | 3,264,410 | 1.03% |
| Man Holdings Pty Ltd | 3,228,750 | 1.02% |
| Pacific Custodians Pty Limited | 2,399,466 | 0.76% |
| Yelwac Pty Ltd | 2,381,804 | 0.75% |
| UBS Nominees Pty Ltd | 2,070,025 | 0.65% |
| Netwealth Investments Limited | 1,955,439 | 0.62% |
| Jean-Francois Chatal | 1,797,069 | 0.57% |
| Warbont Nominees Pty Ltd | 1,753,946 | 0.55% |
